NFKBIA and cancer: In particular, the 790 human glioblastomas analyzed by Bredel and coworkers revealed either an EGFR amplification or an NFKBIA deletion, with heterozygous deletions of NFKBIA being present in 28% of glioblastomas and in 22% of cancer stem-like cells.